Zevra Therapeutics’ (ZVRA) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a report issued on Monday, Benzinga reports.

Separately, HC Wainwright lifted their target price on shares of Zevra Therapeutics from $15.00 to $18.00 and gave the stock a buy rating in a research note on Monday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of Buy and a consensus price target of $20.25.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock remained flat at $7.88 during trading on Monday. 1,443,028 shares of the company were exchanged, compared to its average volume of 376,750. The company has a fifty day moving average of $5.19 and a 200-day moving average of $5.43. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $8.44. The company has a market capitalization of $329.80 million, a price-to-earnings ratio of -5.92 and a beta of 1.97. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.10 and a quick ratio of 2.10.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. The firm had revenue of $3.43 million for the quarter, compared to analysts’ expectations of $3.52 million. Analysts anticipate that Zevra Therapeutics will post -1.57 EPS for the current year.

Insider Activity

In related news, Director John B. Bode acquired 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Friday, July 12th. The shares were purchased at an average cost of $5.87 per share, for a total transaction of $58,700.00. Following the acquisition, the director now owns 30,000 shares in the company, valued at $176,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have bought 22,000 shares of company stock valued at $140,340. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its holdings in Zevra Therapeutics by 134.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock valued at $63,000 after buying an additional 5,545 shares during the period. International Assets Investment Management LLC increased its stake in Zevra Therapeutics by 555.0% during the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after purchasing an additional 5,550 shares during the period. IFG Advisors LLC increased its stake in Zevra Therapeutics by 45.0% during the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after purchasing an additional 5,800 shares during the period. SG Americas Securities LLC increased its stake in Zevra Therapeutics by 41.7% during the fourth quarter. SG Americas Securities LLC now owns 20,999 shares of the company’s stock worth $138,000 after purchasing an additional 6,175 shares during the period. Finally, Rhumbline Advisers increased its stake in Zevra Therapeutics by 17.9% during the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.